203 related articles for article (PubMed ID: 33822549)
1. [Adrenocortical cancer: morphological variants, immunohistochemical characteristics].
Tkachuk AV; Tertychnyi AS; Beltsevich DG; Roslyakova AA; Belousov PV; Selivanova LS
Arkh Patol; 2021; 83(3):10-18. PubMed ID: 33822549
[TBL] [Abstract][Full Text] [Related]
2. Myxoid and Sarcomatoid Variants of Adrenocortical Carcinoma: Analysis of Rare Variants in Single Tertiary Care Center.
Sung TY; Choi YM; Kim WG; Lee YM; Kim TY; Shong YK; Kim WB; Song DE
J Korean Med Sci; 2017 May; 32(5):764-771. PubMed ID: 28378549
[TBL] [Abstract][Full Text] [Related]
3. [Myxoid variant of adrenocortical carcinoma].
Jeremie G; Lifante JC; Chazot FB; Sajous C; Raymond P; Decaussin-Petrucci M
Ann Pathol; 2021 Apr; 41(2):186-191. PubMed ID: 33549334
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases.
Duregon E; Volante M; Bollito E; Goia M; Buttigliero C; Zaggia B; Berruti A; Scagliotti GV; Papotti M
Hum Pathol; 2015 Dec; 46(12):1799-807. PubMed ID: 26472162
[TBL] [Abstract][Full Text] [Related]
5. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
[TBL] [Abstract][Full Text] [Related]
6. Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes.
Parianos C; Kyriakopoulos G; Kostakis ID; Nasiri-Ansari N; Aggeli C; Dimitriadi A; Angelousi A; Papavassiliou AG; Kaltsas GA; Zografos G; Kassi E
Horm Metab Res; 2021 Nov; 53(11):709-716. PubMed ID: 34740271
[TBL] [Abstract][Full Text] [Related]
7. Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants.
de Krijger RR; Papathomas TG
Virchows Arch; 2012 Jan; 460(1):9-18. PubMed ID: 22086150
[TBL] [Abstract][Full Text] [Related]
8. Dissecting Morphological and Molecular Heterogeneity in Adrenocortical Carcinoma.
Duregon E; Volante M; Rapa I; Vatrano S; Papotti M
Turk Patoloji Derg; 2015; 31 Suppl 1():98-104. PubMed ID: 26177320
[TBL] [Abstract][Full Text] [Related]
9. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of immunohistochemical markers in adrenocortical carcinoma.
Zlatibor L; Paunovic I; Zivaljevic V; Dundjerovic D; Tatic S; Djukic V
Acta Chir Belg; 2020 Feb; 120(1):23-29. PubMed ID: 30499377
[No Abstract] [Full Text] [Related]
11. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
Duregon E; Rapa I; Votta A; Giorcelli J; Daffara F; Terzolo M; Scagliotti GV; Volante M; Papotti M
Hum Pathol; 2014 Aug; 45(8):1555-62. PubMed ID: 24890943
[TBL] [Abstract][Full Text] [Related]
12. A novel case of myxoid variant of adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1.
Harada K; Yasuda M; Hasegawa K; Yamazaki Y; Sasano H; Otsuka F
Endocr J; 2019 Aug; 66(8):739-744. PubMed ID: 31118348
[TBL] [Abstract][Full Text] [Related]
13. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
14. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.
Mete O; Erickson LA; Juhlin CC; de Krijger RR; Sasano H; Volante M; Papotti MG
Endocr Pathol; 2022 Mar; 33(1):155-196. PubMed ID: 35288842
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic utility of SF-1 in adrenal cortical tumours.
Maity P; Mondal A; Das R; Sengupta M; Gargari P; Kar A; Sarkar D; Mukhopadhyay S; Chowdhury S; Chatterjee U
Indian J Pathol Microbiol; 2022; 65(4):814-820. PubMed ID: 36308186
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining.
Gan W; Han X; Gong Y; Yang Y; Wang C; Zhang Z
Diagn Pathol; 2024 May; 19(1):71. PubMed ID: 38802933
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic role of SF1, IGF2, Ki67, p53, adiponectin, and leptin receptors in human adrenal cortical tumors.
Babińska A; Pęksa R; Wiśniewski P; Świątkowska-Stodulska R; Sworczak K
J Surg Oncol; 2017 Sep; 116(3):427-433. PubMed ID: 28672049
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.
Wanis KN; Kanthan R
World J Surg Oncol; 2015 Mar; 13():117. PubMed ID: 25889798
[TBL] [Abstract][Full Text] [Related]
19. [Current criteria for the diagnosis of adrenocortical carcinoma].
Selivanova LS; Roslyakova AA; Kovalenko YA; Bogolyubova AV; Tertychnyi AS; Beltsevich DG; Abrosimov AY; Melnichenko GA
Arkh Patol; 2019; 81(3):66-73. PubMed ID: 31317933
[TBL] [Abstract][Full Text] [Related]
20. [Multifactorial assessment of prognostic features of adrenocortical cancer].
Porubayeva EE; Pachuashvili NV; Urusova LS
Arkh Patol; 2022; 84(5):20-27. PubMed ID: 36178218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
